Toxicology Reports
October 11, 2016
Michael T. Williams, Matthew R. Skelton, Ian D. Longacre et al.
3 citations
The abuse of methylenedioxymethamphetamine (MDMA) during pregnancy is of concern. MDMA treatment of rats during a period of brain growth analogous to late human gestation leads to neurochemical and behavioral changes. MDMA from postnatal day (P)11–20 in rats produces reductions in serotonin and deficits in spatial and route-based navigation. In this experiment we examined the impact of MDMA...
The International Journal of Neuropsychopharmacology
January 11, 2013
Tori L. Schaefer, Curtis E. Grace, A Braun et al.
24 citations
Abstract We previously showed that developmental 3,4-methylenedioxymethamphetamine (MDMA) treatment induces long-term spatial and egocentric learning and memory deficits and serotonin (5-HT) reductions. During brain development, 5-HT is a neurotrophic factor influencing neurogenesis, synaptogenesis, migration, and target field organization. MDMA (10 mg/kg × 4/d at 2 h intervals) given on...
J Comp Neurol
August 1, 2012
Ann M. Hemmerle, Jonathan W. Dickerson, Nicole R Herring et al.
29 citations
(±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain.
The open neuropsychopharmacology journal
2012
Devon L Graham, Nicole R Herring, Tori L. Schaefer et al.
4 citations
The abuse of drugs such as methamphetamine (MA), 3,4-methylenedioxymethamphetamine (Ecstasy, MDMA), and 5-methoxydiisopropyltryptamine (5-MeO-DIPT; Foxy) is global. Symptoms from taking these drugs include tachycardia, agitation, hyperpyrexia, and sometimes seizures. We compared the EEG effects of these drugs in male Sprague-Dawley rats (~300 g) implanted with cortical electroencephalographic...
The International Journal of Neuropsychopharmacology
June 28, 2011
Matthew R. Skelton, Devon L. Graham, Tori L. Schaefer et al.
8 citations
Previous findings showed allocentric and egocentric learning deficits in rats after MDMA treatment from postnatal days (PD) 11-20 but not after treatment from PD 1-10. Shorter treatment periods (PD 1-5, 6-10, 11-15, or 16-20) resulted in allocentric learning deficits averaged across intervals but not for any interval individually and no egocentric learning deficits individually or collectively....
Synapse
October 8, 2010
Charles V. Vorhees, Elizabeth He, Matthew R. Skelton et al.
(+)‐Methamphetamine (MA), (±)‐3,4‐methylenedioxymethamphetamine (MDMA), (+)‐amphetamine (AMPH), and (±)‐fenfluramine (FEN) are phenylethylamines with CNS effects. At higher doses, each induces protracted reductions in brain dopamine (DA) and/or serotonin. Chronic MA and MDMA users show persistent monoamine reductions and cognitive impairments. In rats, similar neurochemical effects can be...
Neurotoxicology and Teratology
2010
Devon L Graham, Nicole R Herring, Tori L. Schaefer et al.
13 citations
The use of the club drugs 3,4-methylenedioxymethamphetamine (MDMA) and 5-methoxy-n,n-diisopropyltryptamine (Foxy) is of growing concern, especially as many of the effects, particularly during development, are unknown. The effects of these drugs upon homeostasis may be important since both are known to stimulate the hypothalamic-pituitary-adrenal axis. The purpose of this experiment was to...
Psychopharmacology
June 1, 2009
Matthew R. Skelton, Tori L. Schaefer, Nicole R Herring et al.
31 citations
We have previously shown that (+/-)-3,4-methylenedioxymethamphetamine (MDMA) treatment from postnatal days (P)11 to P20 leads to learning and memory deficits when the animals are tested as adults. Recently, the club drug 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) has gained popularity. Due to the similarities between MDMA and 5-MeO-DIPT and the substitution of 5-MeO-DIPT for MDMA, the...
Developmental Neuroscience
2009
Charles V. Vorhees, Tori L. Schaefer, Matthew R. Skelton et al.
40 citations
During postnatal days (PD) 11–20, (+/–)3,4-methylenedioxymethamphetamine (MDMA) treatment impairs egocentric and allocentric learning, and reduces spontaneous locomotor activity; however, it does not have these effects during PD 1–10. How the learning impairments relate to the stress hyporesponsive period (SHRP) is unknown. To test this association, the preweaning period was subdivided into...
Neuropharmacology
December 2008
Matthew R Skelton, Jessica A Able, Curtis E Grace et al.
3,4-Methlylenedioxymethamphetamine (MDMA) administration (4 x 15 mg/kg) on a single day has been shown to cause path integration deficits in rats. While most animal experiments focus on single binge-type models of MDMA use, many MDMA users take the drug on a recurring basis. The purpose of this study was to compare the effects of repeated single-day treatments with MDMA (4 x 15 mg/kg) once...
International Journal of Developmental Neuroscience
August 1, 2004
Charles V. Vorhees, Tracy M. Reed, Matthew R. Skelton et al.
76 citations
Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) in previous experiments has been shown to induce long‐term spatial and sequential learning and memory deficits in adult offspring after exposure to the drug on postnatal (P) days 11–20, but not after exposure on P1–10. Herein we further tested for the effects of MDMA (0, 5, 10 or 20 mg/kg × 2/day) after exposure on P11–20 on reference and...
Brain Research
March 25, 2003
Michael T. Williams, Laronda L. Morford, Sandra L. Wood et al.
66 citations
Previously, we have shown that rats administered MDMA from postnatal (P) days 11-20 had reductions in body weight during the period of treatment and as adults they had deficits in sequential and spatial learning and memory. In the present study, to control for weight reductions, we used litters with double the number of offspring to induce growth restriction comparable to that of standard size...
Journal of Neuroscience
May 1, 2001
Harry W. Broening, Laronda L. Morford, Sandra L. Inman-Wood et al.
141 citations
Use of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) has increased dramatically in recent years, yet little is known about its effects on the developing brain. Neonatal rats were administered MDMA on days 1–10 or 11–20 (analogous to early and late human third trimester brain development). MDMA exposure had no effect on survival but did affect body weight gain during treatment. After...